ERP Soft Systems (530909)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Market cap of ₹65 crore leaves room for a meaningful re-rating if operations improve.
• Positive book value of ₹20.09 per share provides a small asset backing.
• Price at ₹162.60, near the 52-week high, shows strong market interest and momentum.
• Latest quarter still generated ₹2 crore of sales, indicating an active operating business.

Concerns

• P/E of 85.6 with profit growth of -25% and latest quarterly net profit of ₹0 crore is an extreme disconnect.
• ROE of 1.55% and ROCE of 1.63% are far too low to justify a price-to-book of 8.09.
• Piotroski F-score of 3/9 points to weak financial health and poor fundamentals.
• Sales growth of -7.48% and no dividend yield offer no income or growth cushion.

AI Analysis

Let me start with the numbers. ERP Soft Systems has a market capitalisation of ₹65 crore at ₹162.60 per share. That is a microcap, and microcaps can be wonderful only if the underlying business earns high returns. Here the return on equity is 1.55% and the return on capital employed is 1.63%. For every ₹100 of equity, the company generates less than ₹2 of profit. That is poor economics. Graham said the stock market is a voting machine in the short run and a weighing machine in the long run. The voting machine has taken the price from ₹42.94 to ₹162.60 in 52 weeks, but the weighing machine shows falling sales and flat profits. Sales are down 7.48% and profits are down 25%. The latest quarter shows sales of ₹2 crore and net profit of zero. At a P/E of 85.6 and a price-to-book of 8.09, I am being asked to pay a rich premium for a shrinking, low-return business. Book value is ₹20.09 per share, but the price is 8 times book. The Piotroski F-score of 3 out of 9 reinforces the weak financial position. There is no dividend yield, so I receive no income while waiting. I cannot see a durable moat in these numbers. Perhaps this is a potential turnaround, but a potential turnaround is not enough; I need evidence of recovery. Falling sales, zero quarterly profit, and a price at its 52-week high give me no margin of safety. In Buffett's words, it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price. This is a mediocre company at an expensive price. I would pass, and wait for either a demonstrated improvement in earnings or a much lower valuation.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer